The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillationHiroaki Shimokawa, Hiroshi Inoue, Nobuyoshi Sugishita et al.|International Journal of Cardiology|2018Cited by 48
Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysisIchiro Sakuma, Hiroaki Shimokawa, Shinichiro Uchiyama et al.|Heart and Vessels|2019Cited by 24
Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND studyHirotsugu Atarashi, Hiroaki Shimokawa, Shinichiro Uchiyama et al.|Heart and Vessels|2021Cited by 15
Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial FibrillationTakanori Ikeda, Hiroaki Shimokawa, Hirotsugu Atarashi et al.|The Tohoku Journal of Experimental Medicine|2016Cited by 14
Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillationShinichiro Uchiyama, Hiroaki Shimokawa, Hirotsugu Atarashi et al.|Heart and Vessels|2018Cited by 7